Gadolinium
- Generic Name
- Gadolinium
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- Gd
- CAS Number
- 7440-54-2
- Unique Ingredient Identifier
- AU0V1LM3JT
- Background
Gadolinium is under investigation in Hypertension, ACUTE KIDNEY INJURY, and Chronic Kidney Disease. Gadolinium has been investigated for the basic science of CAD, Multiple Sclerosis, and Coronary Artery Disease.
- Associated Conditions
- -
- Associated Therapies
- -
ASIS for Botox in Cervical Dystonia
Phase 1
- Conditions
- Interventions
- Drug: Efficacy of Botox intramuscularly at Week 6Drug: Adverse Reactions of Botox intramuscularlyDrug: GadoliniumDrug: Efficacy of Botox intramuscularly at Week 12Drug: Adverse Reactions of Botox subdermallyDrug: Efficacy of Botox intramuscularly at Week 18Drug: Efficacy of Botox intramuscularly at Week 24Drug: Efficacy of Botox intramuscularly at Week 30Drug: Efficacy of Botox subdermally at Week 6Drug: Efficacy of Botox subdermally at Week 12Drug: Efficacy of Botox subdermally at Week 18Drug: Efficacy of Botox subdermally at Week 24Drug: Efficacy of Botox subdermally at Week 30
- First Posted Date
- 2014-02-28
- Last Posted Date
- 2015-06-24
- Lead Sponsor
- li nguyen
- Target Recruit Count
- 60
- Registration Number
- NCT02074293
- Locations
- 🇺🇸
Automatic Subdermal Injector System, Inc, Westminster, California, United States
ASIS for Botox in Chronic Migraine
Phase 1
- Conditions
- Interventions
- Drug: GadoliniumDrug: Efficacy of Botox intramuscularly at Week 6Drug: Adverse Reactions of Botox intramuscularlyDrug: Efficacy of Botox intramuscularly at Week 12Drug: Adverse Reactions of Botox subdermallyDrug: Efficacy of Botox intramuscularly at Week 18Drug: Efficacy of Botox intramuscularly at Week 24,Drug: Efficacy of Botox intramuscularly at Week 30Drug: Efficacy of Botox subdermally at Week 6Drug: Efficacy of Botox subdermally at Week 12Drug: Efficacy of Botox subdermally at Week 18Drug: Efficacy of Botox subdermally at Week 24Drug: Efficacy of Botox subdermally at Week 30
- First Posted Date
- 2014-02-28
- Last Posted Date
- 2015-06-24
- Lead Sponsor
- ASIS Corporation
- Target Recruit Count
- 60
- Registration Number
- NCT02074163
- Locations
- 🇺🇸
Automatic Subdermal Injector System, Inc, Westminster, California, United States
Comprehensive Evaluation of Ischemic Heart Disease Using MRI
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-11-04
- Last Posted Date
- 2014-09-26
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 40
- Registration Number
- NCT01234870
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
DSC-MRI With Ferumoxytol and DCE-MRI With Gadolinium in Imaging Vascular Properties in Younger Patients With Brain Tumors
Early Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-09-17
- Last Posted Date
- 2022-08-03
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 14
- Registration Number
- NCT00978562
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
MRI Study With Ferumoxytol in Assessing Early Response in Patients With Glioblastoma Multiforme Receiving Temozolomide and Radiation Therapy
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2017-05-16
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 14
- Registration Number
- NCT00660543
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors
Phase 2
Terminated
- Conditions
- Interventions
- Procedure: 3 Tesla Magnetic Resonance ImagingProcedure: Dynamic Contrast-Enhanced Magnetic Resonance ImagingProcedure: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance ImagingDrug: FerumoxytolDrug: GadoliniumProcedure: High Field Strength Magnetic Resonance ImagingProcedure: Susceptibility Weighted Imaging
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT00659126
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-02-08
- Last Posted Date
- 2022-06-09
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 155
- Registration Number
- NCT00103038
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath